XL765: Clinical Trials

9 completed. 9 Phase 1, 2 Phase 2.

By phase and status

Phase	Trials	Status
Phase 1	9	Completed 9
Phase 2	2	Completed 2

Follow XL765: new trials by email Literature Review of XL765 trials Research Report on XL765

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
Open Label Treatment Extension Study With SAR245408 or SAR245409 as a Monotherapy or as a Combination Regimen SAR245408, SAR245409 - Neoplasm Malignant	Phase 1 / Phase 2	Completed	Sanofi	61	2012-07-20	2022-04-19
A Study of the Safety and Pharmacokinetics of SAR245409 Tablets in Patients With Solid Tumors or Lymphoma SAR245409 - Neoplasm Malignant	Phase 1	Completed	Sanofi	49	2012-06-01	2020-10-28
Study Combining SAR245409 With Rituximab or Bendamustine Plus Rituximab in Patients With Indolent Lymphoma, Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia SAR245409 - Indolent Non-Hodgkin Lymphoma, Mantle Cell Lymphoma	Phase 1	Completed	Sanofi	37	2011-12-01	2016-04-01
Trial of MEK Inhibitor and PI3K/mTOR Inhibitor in Subjects With Locally Advanced or Metastatic Solid Tumors MSC1936369B (pimasertib), SAR245409 (PI3K and mTOR inhibitor) - Locally Advanced Solid Tumor, Metastatic Solid Tumor	Phase 1	Completed	EMD Serono	146	2011-05-01	2017-03-07
Exploratory Study of XL765 (SAR245409) or XL147 (SAR245408) in Subjects With Recurrent Glioblastoma Who Are Candidates for Surgical Resection XL765 (SAR245409), XL147 (SAR245408) - Glioblastoma, Astrocytoma, Grade IV	Phase 1	Completed	Sanofi	40	2011-01-01	2012-07-27
Study of XL147 (SAR245408) or XL765 (SAR245409) in Combination With Letrozole in Subjects With Breast Cancer XL147 (SAR245408), XL765 (SAR245409), letrozole (Femara) - Breast Cancer	Phase 1 / Phase 2	Completed	Sanofi	72	2010-06-01	2016-06-03
A Study of XL765 (SAR245409) in Combination With Temozolomide With and Without Radiation in Adults With Malignant Gliomas XL765 (SAR245409), Temozolomide - Mixed Gliomas, Malignant Gliomas	Phase 1	Completed	Sanofi	54	2008-08-01	2013-04-10
Safety Study of XL765 (SAR245409) in Combination With Erlotinib in Adults With Solid Tumors XL765 (SAR245409), erlotinib - Cancer, Non-Small Cell Lung Cancer	Phase 1	Completed	Sanofi	80	2008-08-01	2012-02-03
Study of the Safety and Pharmacokinetics of XL765 (SAR245409) in Adults With Solid Tumors XL765 (SAR245409) - Cancer	Phase 1	Completed	Sanofi	83	2007-06-01	2013-05-30

Conditions studied

Neoplasms (4)  ·  Breast Neoplasms (2)  ·  Carcinoma, Non-Small-Cell Lung (2)  ·  Glioblastoma (2)  ·  Colorectal Neoplasms (1)  ·  Glioma (1)  ·  Leukemia, Lymphocytic, Chronic, B-Cell (1)  ·  Lymphoma, Mantle-Cell (1)  ·  Melanoma (1)  ·  Neoplasm Metastasis (1)

Sponsors

Sanofi (8)  ·  EMD Serono (1)

Countries

United States (9)  ·  Spain (4)  ·  France (2)  ·  Belgium (1)  ·  Italy (1)

NIH funding

2008 (1)